22:55 IST
NSE
Regulatory Approval
Cipla Regulatory Approval
Cipla received U.S. FDA approval for its Generic Advair Diskus. The product is expected to launch in the U.S. market in Q2 FY 2026-27.
Cipla Ltd
- Share price
- ₹1,333.00
- Market cap
- ₹1,07,689 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 31.9×Sector 47.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 6Employee Stock Options 6Business Update 5Management Change 4Financial Results 4Regulatory Approval 3Earnings Call 3Results Update 2Annual Report 2Annual General Meeting 2Acquisition 2Partnership 1Merger & Restructuring 1Dividend 1Board Meeting Outcome 1Board Meeting Date 1
Time
3 announcements with these filters
09:48 IST
BSE
Regulatory Approval
Cipla Regulatory Approval
Cipla's US subsidiary received final USFDA approval for the first AB-rated generic therapeutic equivalent of Ventolin HFA. The Albuterol Sulfate Inhalation Aerosol is expected to launch in H1 FY 2026-27, targeting a US market valued at $1.5 billion.
16:30 IST
BSE
Regulatory Approval
Cipla Regulatory Approval
Cipla Limited announced the conclusion of a routine cGMP and Pre-Approval Inspection by the USFDA at its Goa facility. The inspection, conducted from April 6-17, 2026, resulted in two inspectional observations in Form 483. The company is committed to addressing these observations within the stipulated timeframe.